Analyst Estimates 30% Slump In GSK’s China Sales Since Anti-Graft Implication
This article was originally published in PharmAsia News
Executive Summary
Since implicated in China’s large-scale anti-graft pharma investigations that began in July, GlaxoSmithKline Plc.’s sales in China have plummeted 30%, an analyst initially estimated.